Paroxysmal atrial fibrillation in patients with sinoatrial blockade undergoing permanent pacing and metabolic therapy

Objective. To study the effect of trimetazidine dihydrochloride on the total number of atrial fibrillation paroxysms in patients with sinus node weakness syndrome and permanent two-chamber pacing. Material and methods. The study included 138 patients with various types of sinoatrial blockades and two-chamber pacing systems. Two groups of patients were formed: 1 — patients receiving metabolic therapy; 2 — patients not receiving metabolic therapy. The effect of trimetazidine dihydrochloride on the total number of atrial fibrillation paroxysms was evaluated in 3 and 12 months after implantation of two-chamber pacing system. All patients of both groups received standard therapy for concomitant diseases. Results. Trimetazidine dihydrochloride in patients with various types of sinoatrial blockades after implantation of two-chamber pacing system reduces the total number of paroxysms of atrial fibrillation. There was a significant (p<0.05) decrease in the number of paroxysms of atrial fibrillation under metabolic therapy in 3 and 12 months after pacing system implantation. Conclusion. Administration of trimethazidine dihydrochloride as a part of complex therapy reduces the total number of paroxysms of atrial fibrillation in patients with sinus node weakness syndrome after implantation of two-chamber pacing system.